Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
Not Applicable
Completed
- Conditions
- Diabetic Nephropathy
- Registration Number
- NCT00240019
- Lead Sponsor
- Stanford University
- Brief Summary
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
proteinuria greater than 1 gram/day serum creatinine < 2.6 for men, < 2.0 for women
Exclusion Criteria
blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method The amount of protein in the urine after 8 weeks of treatment.
- Secondary Outcome Measures
Name Time Method The estimated glomerular filtration rate after 8 weeks of treatment.
Trial Locations
- Locations (2)
Kaiser Permanente of Northern California, Santa Clara and San Jose
🇺🇸Santa Clara, California, United States
Stanford University Medical Center
🇺🇸Stanford, California, United States
Kaiser Permanente of Northern California, Santa Clara and San Jose🇺🇸Santa Clara, California, United States